Vamsidhar Velcheti, MD

Articles

Neoadjuvant Immunotherapy in Resectable NSCLC: The NADIM II and AEGAN Trials

October 7th 2022

Oncologists explain data from the NADIM II and AEGAN clinical trials investigating treatments for neoadjuvant immunotherapy in resectable NSCLC.

The Role of Neoadjuvant Immunotherapy in the Treatment of Resectable NSCLC

September 28th 2022

Myung-Ju Ahn, MD, summarizes the role of neoadjuvant immunotherapy in early-stage NSCLC treatment.

Treatment Options for Early-Stage Non-Small Cell Lung Cancer (NSCLC)

September 28th 2022

Melissa Johnson, MD, and Solange Peters, MD, review the available treatment options for stage I – III non-small cell lung cancer (NSCLC) and how the ESMO guidelines of patient management differ from the NCCN guidelines.

Dr. Velcheti on the Safety of Nemvaleukin in Solid Tumors

June 7th 2022

Vamsidhar Velcheti, MD, discusses the safety of nemvaleukin alfa in patients with advanced solid tumors in the phase 1/2 ARTISTRY-1 trial.

Circling the Latest With ctDNA in Lung Cancer

June 28th 2021

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, discuss the utility with circulating tumor DNA, intriguing data of which were presented during the 2021 ASCO Annual Meeting.

ASCO 2021 Updates With Neoadjuvant Immunotherapy in NSCLC

June 28th 2021

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, cover the latest results with neoadjuvant immunotherapy strategies that were highlighted at the 2021 ASCO Annual Meeting.

What’s Next in HER2+ and Exon 19 Deletions in NSCLC?

June 28th 2021

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, recap the 2021 ASCO Annual Meeting and focus on data presented in patients with non–small cell lung cancer that is HER2 positive or harbors an exon 19 deletion.

Enthusiasm With EGFR Exon 20+ in NSCLC

June 28th 2021

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, highlight the intriguing data in the realm of EGFR exon 21 insertion mutations in non–small cell lung cancer presented during the 2021 ASCO Annual Meeting.

Kicking Off With KRAS in NSCLC

June 28th 2021

OncLive’s third episode of Thoracic Night Live, a program devoted to spotlighting the biggest topics in lung cancer and pivotal studies discussed at medical meetings throughout the year, focuses on findings presented at the 2021 ASCO Annual Meeting.

Dr. Velcheti on the Results of the CodeBreaK 100 Primary Analysis in KRAS G12C+ NSCLC

January 30th 2021

Vamsidhar Velcheti, MD, discusses the results from the primary analysis of the CodeBreaK 100, which examined sotorasib in patients with KRAS G12C–mutated non–small cell lung cancer.

Dr. Velcheti on Potential of Alectinib in Frontline ALK-Positive NSCLC

October 26th 2016

Vamsidhar Velcheti, MD, an assistant professor of Medicine at Cleveland Clinic Lerner School of Medicine, discusses the ALK inhibitor alectinib (Alecensa) and what potential the agent could have in the frontline setting for patients with ALK-positive non–small cell lung cancer (NSCLC). Velcheti shared this insight in an interview during the 2016 OncLive State of the Science Summit on Non–Small Cell Lung Cancer.